ArticleWiley interdisciplinary reviews. Membrane transport and signaling2012
mGlu Receptors and Cancerous Growth.
Article in Wiley interdisciplinary reviews. Membrane transport and signaling, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 34 citations in OpenAlex.
- Polyclonal antibodies selectively inhibit tumor growth and invasion and synergize with immune checkpoint inhibitors.JCI insight · 2024Article
- The evidence for repurposing anti-epileptic drugs to target cancer.Molecular biology reports · 2023Review
- Article
- Regulation of the parental gene GRM4 by circGrm4 RNA transcript and glutamate-mediated neurovascular toxicity in eyes.Molecular and cellular biochemistry · 2021Review
- G Protein-Coupled receptors and heterotrimeric G proteins as cancer drivers.FEBS letters · 2020Review
- Review
- Pathway analysis of glutamate-mediated, calcium-related signaling in glioma progression.Biochemical pharmacology · 2020Review
- Glutamate Receptors and Glioblastoma Multiforme: An Old "Route" for New Perspectives.International journal of molecular sciences · 2019Review
- Metabotropic glutamate receptors as a new therapeutic target for malignant gliomas.Oncotarget · 2017Review
- A systems medicine approach for finding target proteins affecting treatment outcomes in patients with non-Hodgkin lymphoma.PloS one · 2017Article
- The Effect of Cage Shape on Nanoparticle-Based Drug Carriers: Anticancer Drug Release and Efficacy via Receptor Blockade Using Dextran-Coated Iron Oxide Nanocages.Nano letters · 2016Article
- Neurotransmitter signaling pathways required for normal development in Xenopus laevis embryos: a pharmacological survey screen.Journal of anatomy · 2016Article
- Expression of metabotropic glutamate receptor 4 in osteosarcoma.Molecular and clinical oncology · 2016Article
- Article
- Glutamate and its receptors in cancer.Journal of neural transmission (Vienna, Austria : 1996) · 2014Review
- High expression of metabotropic glutamate receptor 4: correlation with clinicopathologic characteristics and prognosis of osteosarcoma.Journal of cancer research and clinical oncology · 2014Article
- BMPs as therapeutic targets and biomarkers in astrocytic glioma.BioMed research international · 2014Review
- Reconstruction of an integrated genome-scale co-expression network reveals key modules involved in lung adenocarcinoma.PloS one · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
G-protein coupled receptors (GPCR) represent a class of therapeutic targets that have been widely exploited for drug designs and development. Metabotropic glutamate receptors (mGluRs) belong to Class C GPCRs and are predominantly involved in maintaining cellular homeostasis in the central nervous system (CNS). The surprising accumulating evidence suggesting other functional roles of mGluRs in human malignancies in addition to synaptic transmission has presented intriguing possibilities to make mGluRs putative novel targets for human cancers. Since our group first described the aberrant expression of mGluR1 as the driving force in melanomagenesis in transgenic mouse models, other subtypes of mGluRs have been implicated in the pathogenesis of various cancer types such as malignant gliomas and medulloblastomas. As such, increased efforts have been generated to elucidate the mechanisms by which mGluRs confer oncogenic potentials. Current knowledge on the participation of various mGluRs in several human cancers suggests that mGluRs are "druggable" members of the GPCR superfamily and their oncogenic implications in cancer, so further understanding on anti-mGluR strategies will be beneficial.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.